Product Description
Mechanisms of Action: GLUR Antagonist,Decarboxylase Inhibitor,COMT Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | France | Germany | Hungary | Ireland | Italy | Korea | Luxembourg | Malta | Netherlands | Portugal | Slovenia | Spain | Switzerland | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: INSTITUT DE CANCEROLOGIE DE L'OUEST
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Brain Cancer|Breast Cancer|Melanoma|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DOPACER | P2 |
Active, not recruiting |
Melanoma|Breast Cancer|Non-Small-Cell Lung Cancer|Brain Cancer |
2023-08-24 |